Alicia Katherine Morgans, MD, MPH
Disclosures: Consulting Fee-AstraZeneca-advisory boards, consulting |Consulting Fee-Bayer Corporation-advisory boards, consulting|Consulting Fee-Janssen-advisory boards, consulting|Consulting Fee-Sanofi-Aventis-advisory boards, consulting, educational talks|Consulting Fee-Genentech, Inc.-advisory boards, consulting|Consulting Fee-Astellas-advisory boards, consulting, educational talks

Alicia Morgans, MD, MPH is an Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois. She completed her MD at the University of Pennsylvania Perelman School of Medicine where she was a member of Alpha Omega Alpha and graduated among the top of her class.  She then completed her internal medicine residency at the Hospital of the University of Pennsylvania, and her fellowship at Dana Farber Cancer Institute/Massachusetts General Hospital Cancer Center. After completing fellowship, she was a faculty member at Vanderbilt University for five years, where she also earned a Master of Public Health degree. Dr. Morgans is currently a clinician and physician investigator at Northwestern University in Chicago where she specializes is investigating complications of systemic therapy for prostate cancer survivors.  Her work has included the study of skeletal, cardiovascular, diabetic, and cognitive complications of prostate cancer survivorship, as well as treatment decision making in the metastatic prostate cancer population. In addition, she has been awarded several federal and foundation grants to investigate the cognitive effects of hormonal treatments in advanced prostate cancer, and treatment decisions in men with metastatic prostate cancer. She also has nationally recognized expertise in patient reported outcome and quality of life studies in men with advanced prostate cancer, as well as incorporating patient preferences and beliefs into clinical decision making.  Dr. Morgans serves as the Principal Investigator for multiple therapeutic prostate cancer and bladder cancer clinical trials at Northwestern, and is an active member of the Eastern Oncology Cooperative Group and the Alliance for Clinical Trials in Oncology.